Evotec AG O.N. (EVTG)

Xetra
Currency in EUR
6.544
-0.024(-0.37%)
Closed·
EVTG Scorecard
Full Analysis
High shareholder yield
EVTG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.5446.760
52 wk Range
5.06010.620
Key Statistics
Edit
Bid/Ask
6.544 / 6.642
Prev. Close
6.568
Open
6.612
Day's Range
6.544-6.76
52 wk Range
5.06-10.62
Volume
1.37M
Average Volume (3m)
1.28M
1-Year Change
-21.68%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVTG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.325
Upside
+73.06%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Evotec AG O.N. News & Analysis

Show more

Evotec AG Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Employees
4766
Market
Germany

Compare EVTG to Peers and Sector

Metrics to compare
EVTG
Peers
Sector
Relationship
P/E Ratio
−5.8x14.7x−0.5x
PEG Ratio
0.040.490.00
Price/Book
1.3x2.4x2.6x
Price / LTM Sales
1.5x4.7x3.0x
Upside (Analyst Target)
63.4%0.0%52.6%
Fair Value Upside
Unlock14.8%8.8%Unlock

Analyst Ratings

4 Buy
4 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.325
(+73.06% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.18 / -0.02
Revenue / Forecast
199.98M / 232.40M
EPS Revisions
Last 90 days

People Also Watch

16.805
UNPI
+1.60%
23.22
FTKn
+0.96%
23.950
DWNG
+1.27%
24.140
LXSG
-0.41%
75.350
GBFG
+1.76%

FAQ

What Is the Evotec AG (EVTG) Share Price Today?

The live Evotec AG share price today is 6.54.

What Stock Exchange Does Evotec AG (EVTG) Trade On?

Evotec AG is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Evotec AG?

The stock symbol (also called a 'ticker') for Evotec AG is "EVTG."

What Is the Current Evotec AG Market Cap?

As of today, Evotec AG market capitalisation is 1.16B.

What Is Evotec AG's (EVTG) Earnings Per Share (TTM)?

The Evotec AG EPS -1.17 (Trailing Twelve Months).

When Is the Next Evotec AG Earnings Date?

Evotec AG's next earnings report will be released on 12 Aug 2025.

Is EVTG a Buy or Sell From a Technical Analyst Perspective?

Based on today's Evotec AG moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Evotec AG Stock Split?

Evotec AG has split 2 times. (See the EVTG stock split history page for full effective split date and price information.)

How Many Employees Does Evotec AG Have?

Evotec AG currently has 4766 employees.

What is the current trading status of Evotec AG (EVTG)?

As of 21 Jun 2025, Evotec AG (EVTG) is trading at a price of 6.54, with a previous close of 6.57. The stock has fluctuated within a day range of 6.54 to 6.76, while its 52-week range spans from 5.06 to 10.62.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.